Persistence of activated myofibroblasts is a hallmark of fibrosis of many organs. Thus, the modulation of the generation/functionality of these cells may represent a strategical anti-fibrotic therapeutic option. Bone marrow derived-mesenchymal stromal cell (MSC)-based therapy has shown promising clues but some criticisms still limit the clinical use of these cells including: the need to avoid xenogeneic compounds contamination for ex vivo cell amplification and the identification of appropriate growth factors acting as pre-conditioning agent and/or cell delivery vehicle during transplantation, thus enabling to improve cell survival in the host tissue microenvironment. Many studies demonstrated the ability of platelet-rich plasma (PRP), a source of many biologically active molecules, to positively influence MSC proliferation, survival and functionality as well as its anti-fibrotic potential. Here we investigated the effects of PRP, murine and human bone marrow derived-MSCs and of the combined treatment PRP/MSCs on in vitro differentiation of murine NIH/3T3 and human HDFα fibroblasts to myofibroblasts induced by transforming growth factor (TGF)-β1, a well-known pro-fibrotic agent. Myofibroblastic phenotype was evaluated morphologically (cell shape and actin cytoskeleton assembly) and immunocitochemically (vinculin-rich focal adhesion clustering, α-smooth muscle actin and type-1 collagen expression). We found that PRP and MSCs, both as single treatments and in combination, were able to prevent the TGF-β1 induced fibroblast-myofibroblast transition. Unexpectedly the combination PRP/MSCs had no synergistic effects. In conclusion, within the limitations related to an in vitro experimentation, our study may contribute to provide experimental background for supporting the anti-fibrotic potential of the combination MSCs/PRP which, once translated “from bench to bedside”, could potentially offer advantages over the single treatments.

Platelet-rich plasma and bone marrow derived-mesenchymal stromal cells prevent TGF-β1 induced myofibroblast generation but are not synergistic when combined: morphological in vitro analysis / Flaminia Chellini, Alessia Tani, Larissa Vallone, Daniele Nosi, Paola Pavan, Franco Bambi, Sandra Zecchi, Chiara Sassoli. - In: CELL TISSUES ORGAN. - ISSN 1422-6421. - ELETTRONICO. - 206(6):(2019), pp. 283-295. [10.1159/000501499]

Platelet-rich plasma and bone marrow derived-mesenchymal stromal cells prevent TGF-β1 induced myofibroblast generation but are not synergistic when combined: morphological in vitro analysis

Flaminia Chellini
Conceptualization
;
Alessia Tani
Investigation
;
Larissa Vallone
Investigation
;
Daniele Nosi
Formal Analysis
;
Paola Pavan
Resources
;
Sandra Zecchi
Writing – Review & Editing
;
Chiara Sassoli
Writing – Original Draft Preparation
2019

Abstract

Persistence of activated myofibroblasts is a hallmark of fibrosis of many organs. Thus, the modulation of the generation/functionality of these cells may represent a strategical anti-fibrotic therapeutic option. Bone marrow derived-mesenchymal stromal cell (MSC)-based therapy has shown promising clues but some criticisms still limit the clinical use of these cells including: the need to avoid xenogeneic compounds contamination for ex vivo cell amplification and the identification of appropriate growth factors acting as pre-conditioning agent and/or cell delivery vehicle during transplantation, thus enabling to improve cell survival in the host tissue microenvironment. Many studies demonstrated the ability of platelet-rich plasma (PRP), a source of many biologically active molecules, to positively influence MSC proliferation, survival and functionality as well as its anti-fibrotic potential. Here we investigated the effects of PRP, murine and human bone marrow derived-MSCs and of the combined treatment PRP/MSCs on in vitro differentiation of murine NIH/3T3 and human HDFα fibroblasts to myofibroblasts induced by transforming growth factor (TGF)-β1, a well-known pro-fibrotic agent. Myofibroblastic phenotype was evaluated morphologically (cell shape and actin cytoskeleton assembly) and immunocitochemically (vinculin-rich focal adhesion clustering, α-smooth muscle actin and type-1 collagen expression). We found that PRP and MSCs, both as single treatments and in combination, were able to prevent the TGF-β1 induced fibroblast-myofibroblast transition. Unexpectedly the combination PRP/MSCs had no synergistic effects. In conclusion, within the limitations related to an in vitro experimentation, our study may contribute to provide experimental background for supporting the anti-fibrotic potential of the combination MSCs/PRP which, once translated “from bench to bedside”, could potentially offer advantages over the single treatments.
2019
206(6)
283
295
Goal 3: Good health and well-being for people
Flaminia Chellini, Alessia Tani, Larissa Vallone, Daniele Nosi, Paola Pavan, Franco Bambi, Sandra Zecchi, Chiara Sassoli
File in questo prodotto:
File Dimensione Formato  
Chellini et al. CTO 2019.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 2.66 MB
Formato Adobe PDF
2.66 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1160926
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact